VP20621
VP20621-200
Phase 2 mab completed
Quick answer
VP20621 for Clostridium Difficile Infection is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Clostridium Difficile Infection
- Phase
- Phase 2
- Modality
- mab
- Status
- completed